Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.
about
Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumabComparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related TolerabilityEfficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesCosts associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs.Patients' conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis.Adherence and resource use among patients treated with biologic drugs: findings from BEETLE studyPhase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication--"It could give me two heads and I'd still try it!"Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter.Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic UseA Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise StudyPatient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis.Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision makingPrioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany.Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach.Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature.Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).Preparing the patient for immunosuppressive therapy.Clinical relevance of target identity and biology: implications for drug discovery and development.Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain.Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications.Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.Patient preferences and satisfaction in a multispecialty infusion center.Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists.Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.Adherence to systemic therapies for immune-mediated inflammatory diseases in Lebanon: a physicians' survey from three medical specialties.Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis.How should impaired morning function in rheumatoid arthritis be treated?Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.An Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-naïve Rheumatoid Arthritis Patients.Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.Patients' willingness to trade off between the duration and frequency of rheumatoid arthritis treatments.UK-South Asian patients' experiences of and satisfaction toward receiving information about biologics in rheumatoid arthritis.Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan.
P2860
Q27023091-F64E0E27-D687-4684-BF0E-D935CCBB71B3Q28550952-F0FBB2C9-7E75-41E9-8AD2-1083E378689CQ33578361-1705F603-1768-4E4F-8125-921D2167A33BQ33691553-036EA992-8147-48E1-9B8A-34788898D54EQ33719245-C80136B6-BE5C-49FC-9367-E9E14B054A45Q33865344-C8C36E1C-1B54-4146-8742-302F376F8370Q34229494-DE8E153A-A09D-4D4D-9C09-0F136BC1A4AEQ34477442-72233763-360C-4AAF-8872-6E9EB7A8412CQ34714711-A08FEB71-F515-4962-B4D7-971F035F63FFQ34770459-13C0EEB5-2A27-46E4-8051-C580615BD1C4Q35554857-35120C5C-A868-4580-80A8-6AE2BC3102DFQ35996755-E8BD902E-630B-4573-85B2-C358EE467A7BQ36205494-ECE5F673-5D8F-4AD3-AB97-4FAB87A1324BQ36868373-DB0E8002-8363-4235-9928-7F16AF466076Q37021279-B67C2F39-C1C1-4395-BDD8-2FD8965777A8Q37358286-F51460D0-3F0F-4712-8A37-67C864B10D45Q37397943-0F8BBB35-125B-4ED6-97EF-4877C0F05D70Q37427086-1573542E-B7CB-4F13-AD1E-8E695EBB82FCQ37536373-3244D7CC-60E3-4426-9684-CAD420D99D37Q37796665-24802191-BBA8-46A7-ABE3-213A74C005CEQ38147723-60357B4E-EEAB-4E75-9E27-B5BA7B59AFC9Q38887484-07B32E08-940B-4C9F-A2FA-624102EECC18Q38898828-520F94E0-2731-4475-B07A-9408770B34AAQ38928600-638D966B-613F-4BE5-8AB9-D182AD781FEEQ40010573-43406B97-028A-4111-8E81-83BB6CA20CE0Q40167433-A2C6674A-7A88-427C-8FDB-3EF8A978BADDQ40405513-E27EB817-43B4-44C9-B010-04C43063E586Q40749335-8BFD2A32-3872-464E-89AE-D100C6266275Q41816131-B05B5352-08DE-4CA3-B289-F82F6D8ADDFBQ42090806-CA3CC4D9-F0BF-4091-81DA-8A9DF9A2900CQ42146734-68D6DC6A-CC1D-4FC1-8BDF-D76E8396249FQ42666679-B6073F88-16D7-4B6E-A5C3-5EBCE75ED728Q44083454-D08BE8A6-0CF4-4BFC-AA30-ACA36069D7ECQ45877225-150EB98A-D46E-4A8E-99B4-CBA5A1F3A79AQ49577384-D321B7AC-6A54-4663-B12E-B721269B779DQ50089602-66FF5FB1-D8CB-4EF3-A21F-8D959176FF39Q50916784-81A1D52F-2EA1-443E-BE2D-F7E58FADEB9FQ51233803-E727D8E2-7A41-42CC-8BA2-ADBE0AEE3205Q52316512-D3B8A491-70A1-4A7B-80AE-D67E70DBFD50Q55341968-E0C17F77-AF2A-4012-A3D6-D9E6A400184D
P2860
Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Patient preferences and satisf ...... thritis with biologic therapy.
@en
Patient preferences and satisf ...... thritis with biologic therapy.
@nl
type
label
Patient preferences and satisf ...... thritis with biologic therapy.
@en
Patient preferences and satisf ...... thritis with biologic therapy.
@nl
prefLabel
Patient preferences and satisf ...... thritis with biologic therapy.
@en
Patient preferences and satisf ...... thritis with biologic therapy.
@nl
P2860
P356
P1476
Patient preferences and satisf ...... thritis with biologic therapy.
@en
P2093
Jennifer L Barton
P2860
P304
P356
10.2147/PPA.S5835
P407
P577
2009-11-29T00:00:00Z